Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2345159 | 1.00 | HRH3 (0.50) | HRH3KCNH2HPGD | |
| SCHEMBL1796952 | 0.87 | HRH3 (0.51) | HRH3KCNH2 | |
| SCHEMBL1796953 | 0.87 | HRH3 (0.51) | HRH3KCNH2 | |
| SCHEMBL2345178 | 0.85 | HRH3 (0.52) | HRH3KCNH2 | |
| SCHEMBL2345183 | 0.85 | HRH3 (0.52) | HRH3KCNH2 | |
| SCHEMBL2343410 | 0.85 | HRH3 (0.51) | HRH3KCNH2 | |
| SCHEMBL2343416 | 0.85 | HRH3 (0.51) | HRH3KCNH2 | |
| SCHEMBL2743789 | 0.84 | HPGD (0.42) | HRH3KCNH2HPGD | |
| SCHEMBL2743790 | 0.84 | HPGD (0.42) | HRH3KCNH2HPGD | |
| SCHEMBL6734430 | 0.84 | HPGD (0.42) | HRH3KCNH2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1868991-B1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2014-07-30 | — | — | EP | claimed |
| US-8178528-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2012-05-15 | — | — | US | claimed |
| US-20100160406-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2010-06-24 | — | — | US | claimed |
| EP-1868991-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-12-26 | — | — | EP | claimed |
| WO-2006107661-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-10-12 | — | — | WO | claimed |
| EP-1784400-B1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2015-01-14 | — | — | EP | disclosed |
| EP-1868991-B1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2014-07-30 | — | — | EP | disclosed |
| EP-1868991-B1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2014-07-30 | — | — | EP | disclosed |
| US-8178528-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178528-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178528-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2012-05-15 | — | — | US | disclosed |
| US-8008301-B2 | (2-(S)-Pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-(4'-trifluoromethyl-biphenyl-4-yl)-methanone; treatment of nervous system disorder, obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY (US) | 2011-08-30 | — | — | US | disclosed |
| US-20070208024-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2007-09-06 | — | — | US | disclosed |
| US-20070208024-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2007-09-06 | — | — | US | disclosed |
| US-20070208024-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2007-09-06 | — | — | US | disclosed |
| EP-1784400-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-05-16 | — | — | EP | disclosed |
| EP-1735278-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2006107661-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006023462-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2005097740-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208024-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | HRH3, HRH4, HCRTR1 | HRH3 1/4885KCNH2 1430/4885HPGD 1172/4885 |
| US-20100160406-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | HRH3, HRH4, HCRTR1 | HRH3 1/4885KCNH2 1678/4885HPGD 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.